Browse by author
Lookup NU author(s): Professor Anne Dickinson,
Dr Anne Lennard,
Dr Rosalind Cartner,
Professor Stephen Proctor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
In this case study an acute lymphoblastic leukaemia (ALL) patient relapsing after autotransplant had remission reinduced with chemotherapy and consolidated after initial response by a course of therapy with recombinant interleukin-2 (rIL-2) given subcutaneously. Immunological parameters measured during therapy demonstrated an increase in the numbers of T cells and in lymphokine-activated killer (LAK) cell activity against autologous leukaemic blasts and LAK-sensitive cell lines. The therapy was well tolerated and administered on an out-patient basis. The patient has remained in haematological remission for over twelve months. Sustained remissions have not been observed previously in relapsed transplant patients using chemotherapy alone. The data suggests that rIL-2 deserves further evaluation in ALL patients who are immunologically intact with residual disease after primary or secondary chemotherapy.
Author(s): Dickinson, A. M., Lennard, A. L., Cartner, R., Proctor, S. J.
Publication type: Article
Publication status: Published
Print publication date: 01/09/1992
ISSN (print): 0887-6924
ISSN (electronic): 1476-5551
PubMed id: 1518307